Effect of the Use of Intranasal Spray of Essential Oils in Patients with Perennial Allergic Rhinitis: A Prospective Study

被引:8
作者
Caimmi, Davide [1 ,2 ]
Neukirch, Catherine [3 ,4 ,5 ]
Louis, Renaud [6 ]
Malard, Olivier [7 ]
Thabut, Gabriel [3 ,4 ,5 ]
Demoly, Pascal [1 ,2 ]
机构
[1] Univ Montpellier, Univ Hosp Montpellier, Dept Pulmonol, Div Allergy,Hop Arnaud de Villeneuve, Montpellier, France
[2] UMRS 1136 INSERM Sorbonne Univ, Equipe EPAR IPLESP, Paris, France
[3] Bichat Claude Bernard Univ Hosp, Dept Pneumol A, Paris, France
[4] Bichat Claude Bernard Univ Hosp, Dept Pneumol B, Paris, France
[5] Bichat Claude Bernard Univ Hosp, INSERM U1152, Paris, France
[6] Univ Liege, Dept Pulm Med, CHU Sart Tilman, IGIGA Res Grp, Liege, Belgium
[7] Univ Hosp Nantes, Hotel Dieu, Serv ORL & Chirurg Cervico Faciale, Nantes, France
关键词
Allergic rhinitis; Essential oils; Management; Control;
D O I
10.1159/000510592
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Introduction: Among allergic rhinitis (AR) symptoms, nasal obstruction particularly affects the quality of life. Antihistamines and intranasal corticosteroids are the most frequently prescribed symptomatic drugs, but their efficacy is often incomplete. Essential oils (EO) have shown an anti-inflammatory effect and potential in treating patients with AR. The aim of this study was to evaluate the effectiveness of a hypertonic EO-based nasal spray on perennial AR (PAR) symptoms. Methods: This prospective, open-label, non-randomized, multicentric trial included 43 patients with PAR sensitized to mites, not controlled for more than a year. All were treated with Puressentiel (R) Respiratory-Decongestant Nasal Spray for 30 days. Their usual treatment remained unchanged during the study period. Before and after treatment, each participant filled out a rhinitis questionnaire, the Allergic Rhinitis Control Test (ARCT). A nasal inspiratory peak flow (NIPF) was performed. Results: The mean ARCT was 16.4 and 20.5 at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 4.1 (p < 0.001). The proportion of patients with controlled rhinitis after 30 days of treatment was 69.8 versus 14% before treatment (p < 0.001). The mean NIPF was 86.5 L/min and 105.1 L/min at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 18.5 L/min. Conclusion: A hypertonic EO-based nasal spray could be a new and natural option in the management of PAR. It could also be used as an add-on therapy when nasal symptoms are not fully controlled.
引用
收藏
页码:182 / 189
页数:8
相关论文
共 27 条
[1]  
Baraniuk James N, 2011, Proc Am Thorac Soc, V8, P62, DOI 10.1513/pats.201006-042RN
[2]   Inhaled 1,8-Cineole Reduces Inflammatory Parameters in Airways of Ovalbumin-Challenged Guinea Pigs [J].
Bastos, Vasco P. D. ;
Gomes, Antoniella S. ;
Lima, Francisco J. B. ;
Brito, Teresinha S. ;
Soares, Pedro M. G. ;
Pinho, Joao P. M. ;
Silva, Claudijane S. ;
Santos, Armenio A. ;
Souza, Marcellus H. L. P. ;
Magalhaes, Pedro J. C. .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 108 (01) :34-39
[3]   Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class [J].
Benninger, Michael ;
Farrar, Judith R. ;
Blaiss, Michael ;
Chipps, Bradley ;
Ferguson, Berrylin ;
Krouse, John ;
Marple, Bradley ;
Storms, William ;
Kaliner, Michael .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2010, 104 (01) :13-29
[4]   Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen) [J].
Bousquet, J. ;
Khaltaev, N. ;
Cruz, A. A. ;
Denburg, J. ;
Fokkens, W. J. ;
Togias, A. ;
Zuberbier, T. ;
Baena-Cagnani, C. E. ;
Canonica, G. W. ;
van Weel, C. ;
Agache, I. ;
Ait-Khaled, N. ;
Bachert, C. ;
Blaiss, M. S. ;
Bonini, S. ;
Boulet, L. -P. ;
Bousquet, P. -J. ;
Camargos, P. ;
Carlsen, K. -H. ;
Chen, Y. ;
Custovic, A. ;
Dahl, R. ;
Demoly, P. ;
Douagui, H. ;
Durham, S. R. ;
van Wijk, R. Gerth ;
Kalayci, O. ;
Kaliner, M. A. ;
Kim, Y. -Y. ;
Kowalski, M. L. ;
Kuna, P. ;
Le, L. T. T. ;
Lemiere, C. ;
Li, J. ;
Lockey, R. F. ;
Mavale-Manuel, S. ;
Meltzer, E. O. ;
Mohammad, Y. ;
Mullol, J. ;
Naclerio, R. ;
Hehir, R. E. O. ;
Ohta, K. ;
Ouedraogo, S. ;
Palkonen, S. ;
Papadopoulos, N. ;
Passalacqua, G. ;
Pawankar, R. ;
Popov, T. A. ;
Rabe, K. F. ;
Rosado-Pinto, J. .
ALLERGY, 2008, 63 :8-+
[5]   Severity and impairment of allergic rhinitis in patients consulting in primary care [J].
Bousquet, J ;
Neukirch, F ;
Bousquet, PJ ;
Gehano, P ;
Klossek, JM ;
Le Gal, M ;
Allaf, B .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) :158-162
[6]  
Choi Y., 2016, EVID BASED COMPLEMEN, V2016
[7]   A Review on Anti-Inflammatory Activity of Monoterpenes [J].
da Silveira e Sa, Rita de Cassia ;
Andrade, Luciana Nalone ;
de Sousa, Damiao Pergentino .
MOLECULES, 2013, 18 (01) :1227-1254
[8]   Validation of a self-questionnaire for assessing the control of allergic rhinitis [J].
Demoly, P. ;
Jankowski, R. ;
Chassany, O. ;
Bessah, Y. ;
Allaert, F-A. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2011, 41 (06) :860-868
[9]   ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France [J].
Demoly, P ;
Allaert, FA ;
Lecasble, M .
ALLERGY, 2002, 57 (06) :546-554
[10]   Rhinitis and sinusitis [J].
Dykewicz, Mark S. ;
Hamilos, Daniel L. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) :S103-S115